DUBLIN--(BUSINESS WIRE)--The "Global Amyotrophic Lateral Sclerosis Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The amyotrophic lateral sclerosis treatment market will register a CAGR of almost 20% by 2023.
Initiatives to increase R&D for new amyotrophic lateral sclerosis therapies will boost the growth of the market
This increase in R&D for new amyotrophic lateral sclerosis therapies is due to the increase in number of cases of amyotrophic lateral sclerosis.
Increase in incidence and prevalence of ALS
The incidence and prevalence of amyotrophic lateral sclerosis is increasing. Amyotrophic lateral sclerosis is commonly known as Lou Gehrig's disease. which is a progressive and fatal neuromuscular disease for which a cure is yet to be identified. The hereditary form of amyotrophic lateral sclerosis is known as familial amyotrophic lateral sclerosis. and it occurs in 5% to 10% of the cases.
Patent expiry of drugs
Loss of patents and market exclusivity of drugs create opportunities for the sales of low-cost alternative drugs, which may decrease the sales of approved drugs. Currently. the market has two drugs, which can delay the progression of the disease and are approved for the treatment of amyotrophic lateral sclerosis.
Key Players
- Italfarmaco
- Mitsubishi Tanabe Pharma
- Sanofi
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY TYPE
- Comparison by type
- Intravenous - Market size and forecast 2018-2023
- Oral - Market size and forecast 2018-2023
- Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Italfarmaco
- Mitsubishi Tanabe Pharma
- Sanofi
For more information about this report visit https://www.researchandmarkets.com/research/2gjz4w/global?w=4